News und Analysen
Sartorius Stedim Biotech SA: Information on Document Availability
Humana Hiring 300 Seasonal Remote Positions
Leading health and well-being company Humana Inc. (NYSE: HUM) announced it is looking to hire about 300 seasonal Enrollment Representatives for nationwide work-from-home positions.
Humana’s
STAAR Surgical to Report Second Quarter Results on August 10, 2022
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award
Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award
Agilent to Announce Third-Quarter Fiscal Year 2022 Financial Results August 16
Agilent Technologies Inc. (NYSE: A) today announced it will release financial results for the third quarter of fiscal year 2022 after the stock market closes on Tuesday, Aug. 16. The company will
Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with ECU Health (formerly Vidant Health), eastern North Carolina’s premier health system. The new
ECU Health Partners With Acadia Healthcare to Build a New Behavioral Health Hospital Expanding Access to Behavioral Health Services
ECU Health and Acadia Healthcare announced today plans to build a state-of-the-art, 144-bed behavioral health hospital in the medical district of Greenville, N.C., less than a mile from ECU Health
Dexcom Canada Achieves Great Place to Work® Certification
Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by
Dexcom Canada Achieves Great Place to Work® Certification
Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
Simulations Plus Realizes Early Success with its Concierge Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Acadia Healthcare Announces Date for Second Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2022 results on Wednesday, July 27, 2022, after the close of the market. Acadia will conduct a
Premier, Inc. to Report Fiscal 2022 Fourth-Quarter and Full-Year Results and Host Conference Call on August 16, 2022
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 fourth quarter and full year on Tuesday, August 16, 2022, at approximately 6:30 a.m. ET. The
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO)(NASDAQ:NBTX)
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: w
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today communicates additional preliminary data
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225